Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor

Cell Biochemistry and Function

Volumn 28, Issue 1, 2010, Pages 66-73

  Yáñez, Rodrigo Ayala ^a   Conn, P Michael ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chaperone; GnRH; GPCR; Hormone action; Protein folding; Protein retention; Receptor

Indexed keywords

CALNEXIN; CHAPERONE; COMPLEMENTARY DNA; GONADORELIN RECEPTOR; MUTANT PROTEIN; OXIDOREDUCTASE; PROTEIN DISULFIDE ISOMERASE; PROTEIN ERP 57; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DISULFIDE BOND; ENDOPLASMIC RETICULUM; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN QUALITY; PROTEIN STABILITY; QUALITY CONTROL; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; CALNEXIN; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPLASMIC RETICULUM; HUMANS; MOLECULAR CHAPERONES; MUTAGENESIS, SITE-DIRECTED; PROTEIN DISULFIDE-ISOMERASES; PROTEIN FOLDING; RECEPTORS, LHRH;

EID: 74049099496     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1622     Document Type: Article

References (48)

1. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-745. DOI: 10.1126/science.289.5480.739.
2. Söderhall JA, Polymeropoulos EE, Paulini K, Gunther E, Kuhne R. Antagonist and agonist binding models of the human gonadotropinreleasing hormone receptor. Biochem Biophys Res Commun 2005; 333: 568-582. DOI: 10.1016/j.bbrc.2005.05.142.
3. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev 2004; 25: 235-275. DOI: 10.1210/er.2003-0002.
4. Davidson JS, Assefa D, Pawson A, et al. Irreversible activation of the gonadotropin-releasing hormone receptor by photoaffinity cross-linking: localization of attachment site to Cys residue in N-terminal segment. Biochemistry 1997; 36: 12881-12889. DOI: 10.1021/bi971377t.
5. Arora KK, Chung HO, Catt KJ. Influence of a species-specific extracelular amino acid on expression and function of the human gonadotropin releasing hormone receptor. Mol Endocrinol 1999; 13: 890-896. DOI: 10.1210/me.13.6.890.
6. Maya-Nuñez G, Janovick JA, Conn PM. Combined modification of intracellular and extracellular loci on human gonadotropin-releasing hormone receptor provides a mechanism for enhanced expression. Endocrine 2000; 13: 401-407. DOI: 10.1385/ENDO:13:3:401.
7. Lin X, Janovick JA, Brothers SP, Blomenrohr M, Bogerd J, Conn PM. Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracelular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Mol Endocrinol 1998; 12: 161-171. DOI: 10.1210/me.12.2.161.
8. Conn PM, Leaños Miranda A, Janovick JA. Protein origami: therapeutic rescue of misfolded gene products. Mol Interv 2002; 2: 308-316. DOI: 10.1124/mi.2.5.308.
9. Leaños-Miranda A, Ulloa-Aguirre A, Janovick JA, Conn PM. In vitro coexpression and pharmacological rescue of mutant gonadotropinreleasing hormona receptors causing hypogonadotrophic hypogonadism in humans expressing compound heterozygous alleles. J Clin Endocrinol Metab 2005; 90: 3001-3008. DOI: 10.1210/jc.2004-2071.
10. Ulloa-Aguirre A, Janovick JA, Leaños Miranda A, Conn PM. Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. Hum Reprod Update 2004; 10: 177-192. DOI: 10.1093/humupd/dmh015.
11. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 2004; 5: 821-837. DOI: 10.1111/j.1600-0854.2004. 00232.x.
12. Janovick JA, Maya Nuñez G, Conn PM. Rescue of hypogonadotropic hypogonadism causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 2002; 87: 3255-3262. DOI: 10.1210/jc.87.7.3255.
13. Brothers SP, Janovick JA, Conn PM. Unexpected effects of epitope and chimeric tags on Gonadotropin-releasing hormone receptors: implications for understanding the molecular etiology of hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2003; 88: 6107-6112. DOI: 10.1210/jc.2003-031047.
14. Dobson CM. Protein folding and misfolding. Nature 2003; 426: 884-890. DOI: 10.1038/nature02261.
15. Stevens FJ, Argon Y. Protein folding in the ER. Semin Cell Dev Biol 1999; 10: 443-454. DOI: 10.1006/scdb. 1999.0315.
16. Ellgaard L. Catalysis of disulphide bond formation in the endoplasmic reticulum. Biochem Soc Trans 2004; 32: 663-667. DOI: 10.1042/BST0320663.
17. Brothers SP, Cornea A, Janovick JA, Conn PM. Human loss of function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. Mol Endocrinol 2004; 18: 1787-1797. DOI: 10.1210/me.2004-0091.
18. Creighton TE, Hillson DA, Freedman RB. Catalysis by protein-disulfide isomerase of the unfolding and refolding of proteins with disulfide bonds. J Mol Biol 1980; 142: 43-62. DOI: 0022-2836(80) 90205-3.
19. Lyles MM, Gilbert HF. Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: pre-steady-state kinetics and the utilization of the utilization of the oxidizing equivalents of the isomerase. Biochemistry 1991; 30: 619-625. DOI: 10.1021/bi00217a005.
20. Olive JD, van der Wal FJ, Bulleid NJ, High S. Interaction of the thiol-dependent reductase ERP-57 with nascent glycoproteins. Science 1997; 275: 86-88. DOI: 10.1126/science.275.5296.86.
21. Koivunen P, Helaakoski T, Annunen P, et al. ERP-60 does not substitute for protein disulphide isomerase as the beta-subunit of prolyl 4 hydroxylase. Biochem J 1996; 316: 599-605.
22. Ferrari DM, Soling HD. The protein disulphide-isomerase family: unraveling a string of folds. Biochem J 1999; 339: 1-10.
23. Frickel EM, Frei P, Bouvier M, et al. ERP-57 is a multifunctional thioldisulfide oxidoreductase. J Biol Chem 2004; 279: 18277-18287. DOI: 10.1074/jbc.M314089200.
24. Srivastava SP, Fuchs JA, Holtzman JL. The reported cDNA sequence for phospholipase C alpha encodes protein disulphide isomerase, isoenzyme Q-2 and not phospholipase-C. Biochem Biophys Res Commun 1993; 193: 971-978. DOI: 10.1006/bbrc. 1993.1720.
25. Antoniou AN, Ford S, Alphey M, Osborne A, Elliott T, Powis SJ. The oxidoreductase ERP-57 efficiently reduces partially folded in preference to fully folded MHC class I molecules. EMBO J 2002; 21: 2655-2663. DOI: 10.1093/emboj/21.11.2655.
26. Hammond C, Braakman I, Helenius A. Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci USA 1994; 91: 913-917.
27. Ware FE, Vassilakos A, Peterson PA, Jackson MR, Lehrman MA, Williams DB. The molecular chaperone calnexin binds GlcMan9Glc-NAc2 oligosaccharide as an initial step in recognizing unfolded glycoproteins. J Biol Chem 1995; 270: 4697-4704. DOI: 10.1074/jbc.270.9.4697.
28. Williams DB. Beyond lectins: the calnexin/Calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006; 119: 615-623. DOI: 10.1242/jcs.02856.
29. Liu Y, Choudhury P, Cabral CM, Sifers RN. Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome. J Biol Chem 1999; 274: 5861-5867. DOI: 10.1074/jbc.274.9.5861.
30. Bedard K, Szabo E, Michalak M, Opas M. Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin and ERP-57. Int Rev Cytol 2005; 245: 91-121. DOI: 10.1016/S0074-7696(05)45004-4.
31. Zapun A, Darby NJ, Tessier DC, Michalak M, Bergeron JJ, Thomas DY. Enhanced catalysis of ribonuclease B folding by the interaction of calnexin or calreticulin with ERP-57. J Biol Chem 1998; 273: 6009-6012. DOI: 10.1074/jbc.273.11.
32. Leach MR, Williams DB. Lectin-deficient calnexin is capable of binding class I histocompatibility molecules in vivo and preventing their degradation. J Biol Chem 2004; 279: 9072-9079. DOI: 10.1074/jbc.M310788200.
33. Oliver JD, Roderick HL, Llewllyn DH, High S. ERP-57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol Biol Cell 1999; 10: 2573-2582. DOI: 10:2573-2582.
34. Frickel EM, Riek R, Jelesarov I, Helenius A, Withrich K, Ellgaard L. TROSY-NMR reveals interaction between ERP-57 and the tip of the calreticulin P-domain. Proc Natl Acad Sci USA 2002; 99: 1954-1959. DOI: 10.1073/pnas.042699099.
35. Leach MR, Cohen-Doyle MF, Thomas DY, Williams DB. Localization of the lectin ERP-57 binding, and polypeptide binding sites of calnexin and calreticulin. J Biol Chem 2002; 277: 29686-29697. DOI: 0.1074/jbc.M202405200.
36. Pollock S, Kozlov G, Pelletier MF, et al. Specific interaction of ERP-57 and calnexin determined by NMR spectroscopy and an ER two-hybrid system. EMBO J 2005; 23: 1020-1029. DOI: 10.1038/sj.emboj.7600119.
37. Roderick HL, Lechleiter JD, Camacho P. Cytosolic phosphorylation of calnexin controls intracellular oscillations via an interaction with SERCA2b. J Cell Biol 2000; 149: 1235-1248.
38. Brothers SP, Janovick JA, Conn PM. Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression. J Mol Endocrinol 2006; 37: 479-488. DOI: 10.1677/jme.1.02142.
39. Janovick JA, Knollman PE, Brothers SP, Ayala-Yañez R, Aziz AS, Conn PM. Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression. J Biol Chem 2006; 281: 8417-8425. DOI: 10.1074/jbc.M510601200.
40. Leaños-Miranda A, Ulloa-Aguirre A, Ji TH, Janovick JA, Conn PM. Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. J Clin Endocrinol Metab 2003; 88: 3360-3367. DOI: 10.1210/jc.2003-030084.
41. Huckle WR, Conn PM. Use of lithium ion in measurement of stimulated pituitary insositol phospholipid turnover. Methods Enzymol 1987; 141: 149-155. DOI: 10.1016/0076-6879(87)41063-X.
42. Russell SJ, Ruddock LW, Salo KE, et al. The primary substrate binding site in the b' domain of ERP-57 is adapted for endoplasmic reticulum lectin association. J Biol Chem 2004; 279: 18861-18869. DOI: 10.1074/jbc.M400575200.
43. Farmery MR, Allen S, Allen AJ, Bulleid NJ. The role of ERP-57 in disulfide bond formation during the assembly of major histocompatibility complex class I in a synchronized semipermeabilized cell translation system. J Biol Chem 2000(275): 14933-14938. DOI: 10.1074/jbc.275.20.14933.
44. Frenkel Z, Shenkman M, Kondratyev M, Lederkremer GZ. Separate roles and different routing of calnexin and ERP-57 in endoplasmic reticulum quality control revealed by interactions with asialoglycoprotein receptor chains. Mol Biol Cell 2004(15): 2133-2142. DOI: 10.1091/mbc.E03-12-0899.
45. Mazzarella RA, Srinivasan M, Haugejorden SM, Green M. ERP-72, an abundant luminar endoplasmic reticulum protein, contains three copies of the active site sequences of protein disulfide isomerase. J Biol Chem 1990; 265: 1094-1101. DOI: 10.1091/mbc.E03-12-0899.
46. Van PN, Rupp K, Lampen A, Soling HD. CaBP2 is a rat homolog of ERP-72 with proteindisulfide isomerase activity. Eur J Biochem 1993; 213: 789-795. DOI: 10.1111/j.1432-1033. 1993.tb17821.x.
47. Satoh M, Shimada A, Keino H, et al. Functional characterization of 3 thioredoxin homology domains of ERP-72. Cell Stress Chaperones 2005; 10: 278-284. DOI: 10.1379/CSC-116R.1.
48. Sorensen S, Ranheim T, Bakken KS, Leren TP, Kulseth MA. Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress. J Biol Chem 2006; 281: 468-476. DOI: 10.1074/jbc.M507071200.